Related Experiment Video
Updated: May 20, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest
E Sick1, A Jeanne, C Schneider
1CNRS, FRE 3481, Matrice Extracellulaire et Dynamique Cellulaire, Université de Reims Champagne-Ardenne, Faculté des Sciences, Reims, France. emilie.sick@univ-reims.fr
Abstract:
CD47 is a ubiquitous 50 kDa five-spanning membrane receptor that belongs to the immunoglobulin superfamily. This receptor, also known as integrin-associated protein, mediates cell-to-cell communication by ligation to transmembrane signal-regulatory proteins SIRPα and SIRPγ and interacts with integrins. CD47 is also implicated in cell-extracellular matrix interactions via ligation with thrombospondins. Furthermore, CD47 is involved in many and diverse cellular processes, including apoptosis, proliferation, adhesion and migration. It also plays a key role in many immune and cardiovascular responses. Thus, this multifaceted receptor might be a central actor in the tumour microenvironment. Solid tumours are composed of not only cancer cells that actively proliferate but also other cell types including immune cells and fibroblasts that make up the tumour microenvironment. Tumour cell proliferation is strongly sustained by continuous sprouting of new vessels, which also represents a gate for metastasis. Moreover, infiltration of inflammatory cells is observed in most neoplasms. Much evidence has accumulated indicating that infiltrating leukocytes promote cancer progression. Given its ubiquitous expression on all the different cell types that compose the tumour microenvironment, targeting CD47 could represent an original therapeutic strategy in the field of oncology. We present a current overview of the biological effects associated with CD47 on cancer cells and stromal cells.
Insights
CD47, a cell surface receptor, plays a crucial role in the tumor microenvironment by influencing cancer and stromal cells. Targeting CD47 offers a promising therapeutic strategy for oncology.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Background:
- CD47 is a ubiquitous 50 kDa membrane receptor from the immunoglobulin superfamily, also known as integrin-associated protein.
- It mediates cell-cell and cell-extracellular matrix interactions, influencing processes like apoptosis, proliferation, adhesion, and migration.
- CD47 is integral to immune and cardiovascular responses and is a key component of the tumor microenvironment.
Purpose of the Study:
- To provide an overview of the biological effects of CD47 on cancer and stromal cells.
- To highlight the potential of CD47 as a therapeutic target in oncology.
- To explore the multifaceted role of CD47 within the tumor microenvironment.
Main Methods:
- Literature review and synthesis of existing research on CD47.
- Analysis of CD47's interactions with SIRPα, SIRPγ, integrins, and thrombospondins.
- Examination of CD47's involvement in cellular processes and immune responses within tumors.
Main Results:
- CD47 is ubiquitously expressed across various cell types within the tumor microenvironment, including cancer cells, immune cells, and fibroblasts.
- Its interactions influence tumor cell proliferation, angiogenesis, and metastasis.
- Infiltrating leukocytes, influenced by CD47, are implicated in promoting cancer progression.
Conclusions:
- CD47's central role in the tumor microenvironment makes it a significant target for therapeutic intervention.
- Targeting CD47 presents an original strategy for cancer treatment.
- Understanding CD47's biological effects is crucial for developing novel oncology therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy